Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes

Rieckmann, Nina; Kronish, Ian M.; Haas, Donald; Gerin, William; Chaplin, William F.; Burg, Matthew M.; Vorchheimer, David A.; Davidson, Karina W.

doi:10.1016/j.ahj.2006.05.014

Cited by 97 publications

(85 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While this makes the study highly relevant to the CAD population, where subsyndromal symptoms predominate, these findings may not apply to those with MDD. Depressive symptoms and subthreshold depression in CAD have been shown to be clinically important, as they predict mortality (Barefoot et al., 2000) and adherence to treatment (Gehi, Haas, Pipkin, & Whooley, 2005; Rieckmann et al., 2006; Ziegelstein et al., 2000). As such, identifying novel treatment targets is of particular importance as milder forms of depression impact prognosis in those with CAD (Barefoot et al., 2000) and are often undertreated (Ellis, Eagle, Kline‐Rogers, & Erickson, 2005).…”

Section: Discussionmentioning

confidence: 99%

Plasma sphingolipids and depressive symptoms in coronary artery disease

et al. 2017

View full text Add to dashboard Cite

BackgroundDepression is highly prevalent in individuals with coronary artery disease (CAD) and increases the risk of future cardiac events and mortality. Sphingolipids have been implicated in the pathophysiology of both CAD and depression. This study assessed the association between plasma sphingolipid concentrations and depressive symptoms in CAD subjects.MethodsDepressive symptoms were measured using the depression subscale of the self‐reported Hospital Anxiety and Depression Scale (HADS). Sphingolipid concentrations were measured from fasting plasma samples using high‐performance liquid chromatography‐coupled electrospray ionization tandem mass spectrometry (LC/MS/MS). Linear regression models were used to assess associations between log‐transformed concentrations of plasma sphingolipids and depressive symptoms.ResultsA total of 111 CAD patients (mean (SD) age = 63.6 ± 6.4, 84.7% male) were included. In linear regression analyses, higher plasma concentrations of ceramides C16:0 (β = 0.204, p = .026) and C18:0 (β = 0.209, p = .023) and sphingomyelin SM18:1 (β = 0.210, p = .024) were significantly associated with higher HADS depression subscale score after adjusting for covariates.ConclusionSphingolipids, in particular the ceramide species C16:0 and C18:0 and the sphingomyelin species SM18:1, may be implicated in the pathophysiology of depression in CAD. The association between plasma sphingolipid concentrations and depression should be further examined in CAD patients and in other populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma sphingolipids and depressive symptoms in coronary artery disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Readily available valid and reliable intruments for this puropose are the Dartmouth COOP, the MacNew, and the Kansas City Cardiomyopathy Questionniare. • reduced chances of successful modification of risk factors (such as smoking cessation) 39,41 • decreased adherence to medical treatment regimens [42][43][44][45] • lower rates of participation in cardiac rehabilitation and reduced quality of life [46][47][48][49] …”

Section: Consequences For Cardiac Rehabilitationmentioning

confidence: 99%

Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology

Pogosova

Saner²,

Pedersen

et al. 2014

Eur J Prev Cardiolog

257

107

View full text Add to dashboard Cite

A large body of empirical research shows that psychosocial risk factors (PSRFs) such as low socio-economic status, social isolation, stress, Type-D personality, depression and anxiety increase the risk of incident coronary heart disease (CHD) and also contribute to poorer health-related quality of life (HRQL) and prognosis in patients with established CHD.PSRFs may also act as barriers to lifestyle changes and treatment adherence and may moderate the effects of cardiac rehabilitation (CR). Furthermore, there appears to be a bidirectional interaction between PSRFs and the cardiovascular system. Stress, anxiety and depression affect the cardiovascular system through immune, neuroendocrine and behavioural pathways. In turn, CHD and its associated treatments may lead to distress in patients, including anxiety and depression. In clinical practice, PSRFs can be assessed with single-item screening questions, standardised questionnaires, or structured clinical interviews.Psychotherapy and medication can be considered to alleviate any PSRF-related symptoms and to enhance HRQOL, but the evidence for a definite beneficial effect on cardiac endpoints is inconclusive. A multimodal behavioural intervention, integrating counseling for PSRFs and coping with illness should be included within comprehensive CR. Patients with clinically significant symptoms of distress should be referred for psychological counseling or psychologically focused interventions and/or psychopharmacological treatment. To conclude, the success of CR may critically depend on the interdependence of the body and mind and this interaction needs to be reflected through the assessment and management of PSRFs in line with robust scientific evidence, by trained staff, integrated within the core CR team. Word count of abstract: 246

show abstract

“…Beyond what many believe to be its pathophysiological effect on the heart, depression is associated with decreased adherence to medications 21,40,45,46 and triple the risk of noncompliance with medical treatment regimens. 47 Depression reduces the chances of successful modifications of other cardiac risk factors 48 and participation in cardiac rehabilitation 49,50 and is associated with higher healthcare utilization and costs 9,51,52 and, not surprisingly, greatly reduced quality of life.…”

mentioning

confidence: 99%

Depression and Coronary Heart Disease

Lichtman¹,

Bigger²,

Blumenthal³

et al. 2008

Circulation

1,214

426

View full text Add to dashboard Cite

Abstract-Depression is commonly present in patients with coronary heart disease (CHD) and is independently associated with increased cardiovascular morbidity and mortality. Screening tests for depressive symptoms should be applied to identify patients who may require further assessment and treatment. This multispecialty consensus document reviews the evidence linking depression with CHD and provides recommendations for healthcare providers for the assessment, referral, and treatment of depression. (Circulation. 2008;118:1768-1775.)

show abstract

Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes

Cited by 97 publications

References 26 publications

Plasma sphingolipids and depressive symptoms in coronary artery disease

Plasma sphingolipids and depressive symptoms in coronary artery disease

Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology

Depression and Coronary Heart Disease

Contact Info

Product

Resources

About